Keryx Biopharma (KERX) Posts Q4 Loss of 44c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures gain as oil pulls back ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
February 25, 2015 4:10 PM ESTNEW YORK, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that corporate presentations will be delivered at the following upcoming investor conferences:
Cowen and Company 35th Annual Health Care Conference (Boston, MA) Presenter: Greg Madison, President and Chief Operating Officer... More



